PKN2 regulates cell-junctions to limit colitis and colon tumour formation
Intestinal barrier failure is a defining feature of inflammatory bowel disease and a key driver of inflammation-associated colorectal cancer. However, the epithelial mechanisms that preserve barrier stability during inflammatory stress remain incompletely defined. Here, we identify the Rho-regulated kinase PKN2 as a non-redundant safeguard of tight junction integrity and a candidate tumour suppressor in colitis-associated colorectal cancer. Conditional PKN2 deletion in mice sensitised the colon to inflammatory injury and significantly increased adenoma formation in an inflammatory cancer model, with tumour burden tightly correlating with colitis severity. Mechanistically, PKN2 localises to tight junctions and is required to stabilise barrier integrity during injury in mouse and organoid models. PKN2 loss induces transcriptional programs conserved in human inflammatory bowel disease, where reduced PKN2 expression associates with increased disease severity and altered therapeutic response. Notably, PKN2 is encoded within genomic loci previously linked to intestinal inflammation susceptibility and tumour suppression in both humans and mice. Our findings identify PKN2 as a functional effector underlying these phenotypes and demonstrate that even heterozygous loss is sufficient to confer heightened sensitivity to inflammatory injury and tumour initiation, positioning PKN2 as a central regulator of tight junction stability that shapes disease severity, treatment response and cancer risk.